Remedium Retatrutide 30mg Pen

Remedium Retatrutide 30mg Pen is a next-generation triple-agonist peptide research compound designed for advanced metabolic studies. Retatrutide targets the GLP-1, GIP, and glucagon receptor pathways simultaneously — making it one of the most innovative research peptides currently being explored in the field of weight regulation, metabolic optimization, and energy balance.

Due to its triple-mechanism profile, Retatrutide has become a key compound of interest in experimental environments examining enhanced appetite regulation, glucose tolerance, lipid metabolism, and overall metabolic efficiency. The pre-filled research pen format allows precise, controlled micro-dosing in laboratory conditions.

Research Profile:

• Compound Type: Triple receptor agonist (GLP-1 / GIP / Glucagon)
• Form: Pre-filled research pen
• Concentration: 30mg
• Purity: ≥98%
• Focus: Appetite modulation, metabolic research, weight management pathways

Research Use Guidelines:

• Administration: Subcutaneous — in research settings only
• Typical study dosing: 0.25–2mg per week depending on protocol
• Store refrigerated to maintain peptide structure and stability

Stacking Notes: Frequently studied alongside NAD+, Semaglutide, or Tirzepatide in metabolic and endocrine research models.

For laboratory and research use only — not for human consumption.